Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287793 · ClinicalTrials.gov registry record · Phase 1
Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01287793: Completed Phase 1 study, sponsored by Pfizer.
NCT01287793 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01287793, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
Administration of a single 50 mg or 200 mg dose of tigecycline will not cause a change in QT/QTc intervals.
Interventions
- DRUG placebo
- DRUG moxifloxacin
- DRUG tigecycline
- DRUG 100 mL 0.9% Sodium Chloride intravenous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
What the finished NCT01287793 record still lists
NCT01287793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT01287793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01287793 about?
NCT01287793 is a clinical study titled "Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects". Administration of a single 50 mg or 200 mg dose of tigecycline will not cause a change in QT/QTc intervals.
What is the current status of trial NCT01287793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2011-01. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01287793?
The interventions under investigation include: placebo (DRUG), moxifloxacin (DRUG), tigecycline (DRUG), 100 mL 0.9% Sodium Chloride intravenous (DRUG).
Who is sponsoring clinical trial NCT01287793?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01287793's enrollment target sits among peer trials
48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia